These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36315970)

  • 1. The health and economic impact of switching vaccines in universal varicella vaccination programs using a dynamic transmission model: An Israel case study.
    Kujawski SA; Burgess C; Agi O; Attias-Geva Z; Pillsbury M; Greenberg D; Bencina G; Pawaskar M
    Hum Vaccin Immunother; 2022 Nov; 18(6):2124784. PubMed ID: 36315970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom.
    Akpo EIH; Cristeau O; Hunjan M; Casabona G
    Clin Infect Dis; 2021 Dec; 73(11):e3617-e3626. PubMed ID: 33173938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical and economic costs associated with regional disparities in varicella vaccine coverage in Italy over 50 years (2020-2070).
    Lang JC; Samant S; Cook JR; Ranjan S; Senese F; Starnino S; Giuffrida S; Azzari C; Baldo V; Pawaskar M
    Sci Rep; 2024 May; 14(1):11929. PubMed ID: 38789451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland.
    Heininger U; Pillsbury M; Samant S; Lienert F; Guggisberg P; Gani R; O'Brien E; Pawaskar M
    Pediatr Infect Dis J; 2021 Jun; 40(6):e217-e221. PubMed ID: 33872276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.
    Littlewood KJ; Ouwens MJ; Sauboin C; Tehard B; Alain S; Denis F
    Clin Ther; 2015 Apr; 37(4):830-841.e7. PubMed ID: 25721380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of 2-dose routine measles, mumps, rubella, and varicella vaccination in France on the epidemiology of varicella and zoster using a dynamic model with an empirical contact matrix.
    Ouwens MJ; Littlewood KJ; Sauboin C; Téhard B; Denis F; Boëlle PY; Alain S
    Clin Ther; 2015 Apr; 37(4):816-829.e10. PubMed ID: 25726457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Slovenia.
    Burgess C; Kujawski S; Lapornik A; Bencina G; Pawaskar M
    J Health Econ Outcomes Res; 2022; 9(2):95-102. PubMed ID: 36196453
    [No Abstract]   [Full Text] [Related]  

  • 8. Universal varicella vaccination in Denmark: Modeling public health impact, age-shift, and cost-effectiveness.
    Burgess C; Samant S; leFevre T; Schade Larsen C; Pawaskar M
    PLOS Glob Public Health; 2023; 3(4):e0001743. PubMed ID: 37018165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative efficacy of varicella vaccines: network meta-analysis of randomized controlled trials.
    Pawaskar M; Siddiqui MK; Takyar J; Sharma A; Fergie J
    Curr Med Res Opin; 2022 Oct; 38(10):1772-1782. PubMed ID: 35713564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella.
    Ramet J
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S49-55. PubMed ID: 18162247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varicella vaccination in Italy and Germany - different routes to success: a systematic review.
    Kauffmann F; Bechini A; Bonanni P; Casabona G; Wutzler P
    Expert Rev Vaccines; 2020 Sep; 19(9):843-869. PubMed ID: 32969747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T; McIntyre P; Roberton D; Descamps D
    Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies.
    Azzari C; Baldo V; Giuffrida S; Gani R; O'Brien E; Alimenti C; Daniels VJ; Wolfson LJ
    Clinicoecon Outcomes Res; 2020; 12():273-283. PubMed ID: 32606844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling Hospitalisation Ratios for Febrile Convulsions and Severe Varicella Under Combined Measles, Mumps, Rubella, and Varicella (MMRV-Priorix-Tetra™) Compared to Separate MMR + V Vaccination.
    Bauchau V; Van Holle L; Cohen C
    Drug Saf; 2015 Nov; 38(11):1095-102. PubMed ID: 26251259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of the combined MMRV Priorix-Tetra™ vaccine against varicella in a large Italian region: A case-control study.
    Fortunato F; Musco A; Iannelli G; Meola M; Luigi Lopalco P; Martinelli D
    Vaccine; 2024 Mar; 42(7):1608-1616. PubMed ID: 38341290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
    Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
    Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.